Trial record 1 of 1 for:    NCT01683188
Previous Study | Return to List | Next Study

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma (PROCLIVITY 01)

This study is currently recruiting participants.
Verified March 2014 by Prometheus Laboratories
Sponsor:
Information provided by (Responsible Party):
Prometheus Laboratories
ClinicalTrials.gov Identifier:
NCT01683188
First received: September 7, 2012
Last updated: March 13, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)